The Effect of genetic polymorphism of CYP2B6 and UGT1A9 on the Pharamcokinetics and Pharmacodynamics of Propofol

UMIN ID: UMIN000002009

Registered date:26/05/2009

Basic Information

• Recruitment status: Complete: follow-up continuing
• Health condition(s) or Problem(s) studied: The patients are surgical operation with propofol in the St. Marianna University Hospital
• Date of first enrollment: 2009/06/01
• Target sample size: 100
• Countries of recruitment: Japan
• Study type: Observational

Outcome(s)

• Primary Outcome: The recovery of consciousness time, polymorphism of CYP2B6 and UGT1A9
• Secondary Outcome: Pharmacokinetics parameter of propofol

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: The patients did not informed consent. The propofol administration dosage is varied. The patients are transfusion during surgical operation. The patients have infection. The patients is under the confusion, ileus, agnosis, resection of stomach, disorder of liver function, disorder of kidney function, suppress of breathing, chronic obstructive pulmonary disease, asthma, heart failure with chronic pulmonary disease, and/or seizure. The medical doctor is estimate that the patients cannot entry of study

Related Information

• Primary Sponsor: St. Marianna University School of Medicine, Department of Pharmacogenomics
• Secondary Sponsor: St. Marianna University School of Medicine, Department of Anesthesiology., Showa Pharmaceutical University, Department of Drug Metabolism and Pharmacokinetics
• Source(s) of Monetary Support: St. Marianna University School of Medicine, Department of Pharmacogenomics